Immunohistochemical expression of programmed death-ligand 1 and CD8 in glioblastomas

Background Glioblastoma is the most aggressive primary malignant brain tumor in adults and is characterized by poor prognosis. Immune evasion occurs via programmed death-ligand 1 (PD-L1)/programmed death receptor 1 (PD-1) interaction. Some malignant tumors have responded to PD-L1/PD-1 blockade treat...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Dina Mohamed El Samman, Manal Mohamed El Mahdy, Hala Sobhy Cousha, Zeinab Abd El Rahman Kamar, Khaled Abdel Karim Mohamed, Hoda Hassan Abou Gabal
Formato:	article
Lenguaje:	EN KO
Publicado:	Korean Society of Pathologists & the Korean Society for Cytopathology 2021
Materias:	glioblastoma programmed death ligand 1 tumor-infiltrating lymphocytes cd8 survival analysis Pathology RB1-214
Acceso en línea:	https://doaj.org/article/791d96d5a4c74fff91e581c3a53bb312
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:791d96d5a4c74fff91e581c3a53bb312
record_format	dspace
spelling	oai:doaj.org-article:791d96d5a4c74fff91e581c3a53bb3122021-11-18T05:29:08ZImmunohistochemical expression of programmed death-ligand 1 and CD8 in glioblastomas2383-78372383-784510.4132/jptm.2021.08.04https://doaj.org/article/791d96d5a4c74fff91e581c3a53bb3122021-11-01T00:00:00Zhttp://www.jpatholtm.org/upload/pdf/jptm-2021-08-04.pdfhttps://doaj.org/toc/2383-7837https://doaj.org/toc/2383-7845Background Glioblastoma is the most aggressive primary malignant brain tumor in adults and is characterized by poor prognosis. Immune evasion occurs via programmed death-ligand 1 (PD-L1)/programmed death receptor 1 (PD-1) interaction. Some malignant tumors have responded to PD-L1/PD-1 blockade treatment strategies, and PD-L1 has been described as a potential predictive biomarker. This study discussed the expression of PD-L1 and CD8 in glioblastomas. Methods Thirty cases of glioblastoma were stained immunohistochemically for PD-L1 and CD8, where PD-L1 expression in glioblastoma tumor tissue above 1% is considered positive and CD-8 is expressed in tumor infiltrating lymphocytes. The expression of each marker was correlated with clinicopathologic parameters. Survival analysis was conducted to correlate progression-free survival (PFS) and overall survival (OS) with PD-L1 and CD8 expression. Results Diffuse/fibrillary PD-L1 was expressed in all cases (mean expression, 57.6%), whereas membranous PD-L1 was expressed in six of 30 cases. CD8-positive tumor-infiltrating lymphocytes (CD8+ TILs) had a median expression of 10%. PD-L1 and CD8 were positively correlated (p = .001). High PD-L1 expression was associated with worse PFS and OS (p = .026 and p = .001, respectively). Correlation of CD8+ TILs percentage with age, sex, tumor site, laterality, and outcomes were statistically insignificant. Multivariate analysis revealed that PD-L1 was the only independent factor that affected prognosis. Conclusions PD-L1 expression in patients with glioblastoma is robust; higher PD-L1 expression is associated with lower CD8+ TIL expression and worse prognosis.Dina Mohamed El SammanManal Mohamed El MahdyHala Sobhy CoushaZeinab Abd El Rahman KamarKhaled Abdel Karim MohamedHoda Hassan Abou GabalKorean Society of Pathologists & the Korean Society for Cytopathologyarticleglioblastomaprogrammed death ligand 1tumor-infiltrating lymphocytescd8survival analysisPathologyRB1-214ENKOJournal of Pathology and Translational Medicine, Vol 55, Iss 6, Pp 388-397 (2021)
institution	DOAJ
collection	DOAJ
language	EN KO
topic	glioblastoma programmed death ligand 1 tumor-infiltrating lymphocytes cd8 survival analysis Pathology RB1-214
spellingShingle	glioblastoma programmed death ligand 1 tumor-infiltrating lymphocytes cd8 survival analysis Pathology RB1-214 Dina Mohamed El Samman Manal Mohamed El Mahdy Hala Sobhy Cousha Zeinab Abd El Rahman Kamar Khaled Abdel Karim Mohamed Hoda Hassan Abou Gabal Immunohistochemical expression of programmed death-ligand 1 and CD8 in glioblastomas
description	Background Glioblastoma is the most aggressive primary malignant brain tumor in adults and is characterized by poor prognosis. Immune evasion occurs via programmed death-ligand 1 (PD-L1)/programmed death receptor 1 (PD-1) interaction. Some malignant tumors have responded to PD-L1/PD-1 blockade treatment strategies, and PD-L1 has been described as a potential predictive biomarker. This study discussed the expression of PD-L1 and CD8 in glioblastomas. Methods Thirty cases of glioblastoma were stained immunohistochemically for PD-L1 and CD8, where PD-L1 expression in glioblastoma tumor tissue above 1% is considered positive and CD-8 is expressed in tumor infiltrating lymphocytes. The expression of each marker was correlated with clinicopathologic parameters. Survival analysis was conducted to correlate progression-free survival (PFS) and overall survival (OS) with PD-L1 and CD8 expression. Results Diffuse/fibrillary PD-L1 was expressed in all cases (mean expression, 57.6%), whereas membranous PD-L1 was expressed in six of 30 cases. CD8-positive tumor-infiltrating lymphocytes (CD8+ TILs) had a median expression of 10%. PD-L1 and CD8 were positively correlated (p = .001). High PD-L1 expression was associated with worse PFS and OS (p = .026 and p = .001, respectively). Correlation of CD8+ TILs percentage with age, sex, tumor site, laterality, and outcomes were statistically insignificant. Multivariate analysis revealed that PD-L1 was the only independent factor that affected prognosis. Conclusions PD-L1 expression in patients with glioblastoma is robust; higher PD-L1 expression is associated with lower CD8+ TIL expression and worse prognosis.
format	article
author	Dina Mohamed El Samman Manal Mohamed El Mahdy Hala Sobhy Cousha Zeinab Abd El Rahman Kamar Khaled Abdel Karim Mohamed Hoda Hassan Abou Gabal
author_facet	Dina Mohamed El Samman Manal Mohamed El Mahdy Hala Sobhy Cousha Zeinab Abd El Rahman Kamar Khaled Abdel Karim Mohamed Hoda Hassan Abou Gabal
author_sort	Dina Mohamed El Samman
title	Immunohistochemical expression of programmed death-ligand 1 and CD8 in glioblastomas
title_short	Immunohistochemical expression of programmed death-ligand 1 and CD8 in glioblastomas
title_full	Immunohistochemical expression of programmed death-ligand 1 and CD8 in glioblastomas
title_fullStr	Immunohistochemical expression of programmed death-ligand 1 and CD8 in glioblastomas
title_full_unstemmed	Immunohistochemical expression of programmed death-ligand 1 and CD8 in glioblastomas
title_sort	immunohistochemical expression of programmed death-ligand 1 and cd8 in glioblastomas
publisher	Korean Society of Pathologists & the Korean Society for Cytopathology
publishDate	2021
url	https://doaj.org/article/791d96d5a4c74fff91e581c3a53bb312
work_keys_str_mv	AT dinamohamedelsamman immunohistochemicalexpressionofprogrammeddeathligand1andcd8inglioblastomas AT manalmohamedelmahdy immunohistochemicalexpressionofprogrammeddeathligand1andcd8inglioblastomas AT halasobhycousha immunohistochemicalexpressionofprogrammeddeathligand1andcd8inglioblastomas AT zeinababdelrahmankamar immunohistochemicalexpressionofprogrammeddeathligand1andcd8inglioblastomas AT khaledabdelkarimmohamed immunohistochemicalexpressionofprogrammeddeathligand1andcd8inglioblastomas AT hodahassanabougabal immunohistochemicalexpressionofprogrammeddeathligand1andcd8inglioblastomas
_version_	1718424919812866048

Immunohistochemical expression of programmed death-ligand 1 and CD8 in glioblastomas

Ejemplares similares